title: The percentage of core involved by cancer is the best predictor of insignificant prostate cancer, according to an updated definition (tumor volume up to 2.5 cm3): analysis of a cohort of 210 consecutive patients with low-risk disease.
abstract: OBJECTIVE
  To find out which factors could predict the diagnosis of insignificant prostate cancer (ins-PCa) according to a recently updated definition (overall tumor volume up to 2.5 cm(3); final Gleason score ≤6; organ-confined disease) on a prostatic biopsy specimen.
  
  
  METHODS
  This was a retrospective analysis of 210 patients undergoing radical prostatectomy for a cT1c prostate neoplasm with a biopsy specimen Gleason score of ≤6. A logistic regression model was used to assess the differences in the distribution of some possibly predictive factors between the ins-PCa patients, according to the updated definition, and the remaining patients.
  
  
  RESULTS
  By applying an updated definition of ins-PCa, the prevalence of this condition increased from 13.3% to 49.5% (104 of 210 patients). The univariate analysis showed a statistically different distribution of the following factors: prostate-specific antigen density, prostate volume, number of cancer-involved cores, and maximum percentage of core involvement by cancer. At the multivariable analysis, the maximum percentage of involvement of the core retained its relevance (27.0% in ins-PCa patients and 43.8% in the remaining patients; hazard ratio, 0.972; P = .046), and a 20% cutoff was detected.
  
  
  CONCLUSIONS
  In a cohort of patients with PCa cT1c and a biopsy specimen Gleason score of ≤6, the ins-PCa rate, according to the updated definition, is close to 50%, and the percentage of cancer involvement of the core is the single factor that best predicts this diagnosis.
authors.affiliation: Department of Urology, Spedali Civili Hospital and University of Brescia, Brescia, Italy. Electronic address: alxanto@hotmail.com.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Antonelli
authors.affiliation: Department of Urology, Spedali Civili Hospital and University of Brescia, Brescia, Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Vismara Fugini
authors.affiliation: Department of Pathology, Spedali Civili Hospital and University of Brescia, Brescia, Italy.
authors.forename: Regina
authors.initials: R
authors.lastname: Tardanico
authors.affiliation: Department of Urology, Spedali Civili Hospital and University of Brescia, Brescia, Italy.
authors.forename: Luca
authors.initials: L
authors.lastname: Giovanessi
authors.affiliation: Department of Urology, Spedali Civili Hospital and University of Brescia, Brescia, Italy.
authors.forename: Tiziano
authors.initials: T
authors.lastname: Zambolin
authors.affiliation: Department of Urology, Spedali Civili Hospital and University of Brescia, Brescia, Italy.
authors.forename: Claudio
authors.initials: C
authors.lastname: Simeone
mesh_terms: D015331:Cohort Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000473:pathology*; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D047368:Tumor Burden